The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The initial consideration for the transaction is US$ 12 million
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated